Molecular analysis of fine-needle aspiration biopsies (FNAB) improves the diagnostic accuracy of indeterminate thyroid nodules (ITNs) as previously demonstrated with the use of multiplatform molecular testing (MPTX) combining mutational analysis (ThyGeNEXT®) with quantitative microRNA (miRNA) expression (ThyraMIR®).1 Recently, MPTXv2 (ThyGeNEXT + ThyraMIR®v2) has been shown to further improve the accurate risk stratification of ITNs with the use of miRNA pairwise expression.2
Clinical Utility of a Mutation Panel Used in Combination With an Expanded microRNA Risk Classifier in Indeterminate Thyroid Nodules: A Large Real-world Observational Study
ATA Annual Meeting 2022
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.
